title: Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs.
abstract: Along with the improvement of survival after cancer, cardiotoxicity due to antineoplastic treatments has emerged as a clinically relevant problem. Potential cardiovascular toxicities due to anticancer agents include QT prolongation and arrhythmias, myocardial ischemia and infarction, hypertension and/or thromboembolism, left ventricular (LV) dysfunction, and heart failure (HF). The latter is variable in severity, may be reversible or irreversible, and can occur soon after or as a delayed consequence of anticancer treatments. In the last decade recent advances have emerged in clinical and pathophysiological aspects of LV dysfunction induced by the most widely used anticancer drugs. In particular, early, sensitive markers of cardiac dysfunction that can predict this form of cardiomyopathy before ejection fraction (EF) is reduced are becoming increasingly important, along with novel therapeutic and cardioprotective strategies, in the attempt of protecting cardiooncologic patients from the development of congestive heart failure.
authors.affiliation: Department of Medicine and Health Sciences, University of Molise, 86100 Campobasso, Italy.
authors.forename: Marilisa
authors.initials: M
authors.lastname: Molinaro
authors.affiliation: Department of Internal Medicine, University of Genova, 16132 Genova, Italy.
authors.forename: Pietro
authors.initials: P
authors.lastname: Ameri
authors.affiliation: Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy.
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Marone
authors.affiliation: Department of Translational Medical Sciences, Division of Internal Medicine, Federico II University, 80131 Naples, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Petretta
authors.affiliation: Department of Translational Medical Sciences, Division of Internal Medicine, Federico II University, 80131 Naples, Italy.
authors.forename: Pasquale
authors.initials: P
authors.lastname: Abete
authors.affiliation: Department of Biomedical Sciences, University of Padova, 35121 Padova, Italy ; National Researches Council, Neuroscience Institute, University of Padova, 35121 Padova, Italy.
authors.forename: Fabio
authors.initials: F
authors.lastname: Di Lisa
authors.affiliation: Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy.
authors.forename: Sabino
authors.initials: S
authors.lastname: De Placido
authors.affiliation: Department of Translational Medical Sciences, Division of Internal Medicine, Federico II University, 80131 Naples, Italy.
authors.forename: Domenico
authors.initials: D
authors.lastname: Bonaduce
authors.affiliation: Department of Translational Medical Sciences, Division of Internal Medicine, Federico II University, 80131 Naples, Italy.
authors.forename: Carlo G
authors.initials: CG
authors.lastname: Tocchetti
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D066126:Cardiotoxicity / Q000503:physiopathology; D002319:Cardiovascular System / Q000187:drug effects / Q000503:physiopathology; D006331:Heart Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013923:Thromboembolism; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents